Phase 1 and 3 trials demonstrated improved survival rates, with new treatment strategies for EGFR-mutated NSCLC, HER2+ breast cancer, and small-cell lung cancer. AI innovations, such as the ASCO ...
Impact of piflufolastat F18 imaging on disease management for prostate cancer patients: Observations from the PYLARIFY Registry study. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results